$AGIO Recent Headlines 15 small-cap stocks Goldman

New Post Public Reply Private Reply Replies (0) Message Board

Sep 17, 2014 at 1:23 PM

$AGIO Recent Headlines

15 small-cap stocks Goldman Sachs says are worth a look 11:51 a.m. July 22, 2014 - blogs.marketwatch.com
Stock futures drop as earnings season looms 9:20 a.m. April 7, 2014 - Sara Sjolin
Agios shares rally 6.4% premarket after upbeat trial results 7:28 a.m. April 7, 2014 - Sara Sjolin

Jim Cramer's Top Stock Picks: AGIO AAPL LUV 6:00 a.m. Today - TheStreet.com
Cramer's Mad Money - The World Is Slowing, And Slowing Fast (9/16/14) 5:29 a.m. Today - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Let's Hear It for the Bull 8:20 p.m. Sept. 16, 2014 - TheStreet.com
Agios Pharmaceuticals (AGIO): Today's Weak On High Volume Stock 10:08 a.m. Sept. 12, 2014 - TheStreet.com
9 Biotechnology Stocks to Buy Now 6:00 a.m. Aug. 27, 2014 - InvestorPlace.com
Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Q2 2014 Results - Earnings Call Transcript 4:10 p.m. Aug. 9, 2014 - Seeking Alpha
10-Q: AGIOS PHARMACEUTICALS INC 5:18 p.m. Aug. 7, 2014 - Edgar Online - (EDG = 10Q, 10K)
8 Biotechnology Stocks to Buy Now 5:00 a.m. Aug. 6, 2014 - InvestorPlace.com
Goldman's picks in small caps 12:45 p.m. Aug. 5, 2014 - Seeking Alpha
25 Small-Cap Stocks to Buy 8:18 a.m. July 23, 2014 - InvestorPlace.com
Agios Presents Data on AG-221 - Analyst Blog 5:21 p.m. June 16, 2014 - Zacks.com
Agios drug designated an orphan drug for AML 8:58 a.m. June 16, 2014 - Seeking Alpha
Biotech Stocks Get Turbo Boost From Idenix Deal 6:45 p.m. June 11, 2014 - Seeking Alpha
Agios Initiates Trial on AG-348 - Analyst Blog 4:35 p.m. June 10, 2014 - Zacks.com
Bluebird, Agios: Preview of Next Week's Important Pipeline Updates 8:03 a.m. June 6, 2014 - TheStreet.com
SA PRO: Top Long And Short Ideas, Friday May 16 5:00 a.m. May 17, 2014 - Seeking Alpha
J.P.Morgan's Geoff Meacham Plucks Biotechs With Upside From A Down Market 9:17 a.m. May 16, 2014 - Seeking Alpha
Wall Street Breakfast: Must-Know News 6:34 a.m. May 16, 2014 - Seeking Alpha
10-Q: AGIOS PHARMACEUTICALS INC 4:07 p.m. May 9, 2014 - Edgar Online - (EDG = 10Q, 10K)
Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Q1 2014 Results - Earnings Call Transcript 1:43 p.m. May 8, 2014 - Seeking Alpha

Flagship Ventures Appoints Agricultural Industry Leader Robert Berendes as Venture Partner 9:00 a.m. Aug. 25, 2014 - PR Newswire - PRF
Agios Pharmaceuticals Announces the U.S. FDA Grants Fast Track Designation to AG-221 for Treatment of Patients With Acute Myelogenous Leukemia That Harbor an IDH2 Mutation 8:30 a.m. Aug. 13, 2014 - GlobeNewswire
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Agios Pharmaceuticals, Inc. Regarding Possible Breaches of Fiduciary Duty 1:38 p.m. Aug. 12, 2014 - BusinessWire - BZX
Agios Pharmaceuticals Reports Second Quarter 2014 Financial Results 7:31 a.m. Aug. 7, 2014 - GlobeNewswire
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Agios Pharmaceuticals, Inc. Regarding Possible Breaches of Fiduciary Duty 11:14 a.m. July 31, 2014 - BusinessWire - BZX
Agios Pharmaceuticals to Webcast Conference Call of Second Quarter 2014 Financial Results on August 7, 2014 9:01 a.m. July 28, 2014 - GlobeNewswire
Acquisition Agreements, Rejected Acquisition Tender Offers, Appointment, and Technical Updates - Research Reports on Pfizer, Gentiva, bluebird bio, Agios and AcelRx 8:30 a.m. July 23, 2014 - PR Newswire - PRF
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Agios Pharmaceuticals, Inc. Regarding Possible Breaches of Fiduciary Duty 1:30 p.m. July 15, 2014 - PR Newswire - PRF
Flagship Ventures Adds Pharma Industry Veteran Roger J. Pomerantz, M.D., F.A.C.P. as Senior Partner 9:00 a.m. July 14, 2014 - PR Newswire - PRF
Orphan Drug Designations, Financial Results, Board Elections, and Raised Financial Guidance - Analyst Notes on Agios, Alder, Healthways, NeoGenomics and Sequenom 6:10 a.m. July 2, 2014 - PR Newswire - PRF
Agios Pharmaceuticals Announces Orphan Drug Designation of AG-221 for Treatment of Acute Myelogenous Leukemia 8:02 a.m. June 16, 2014 - BusinessWire - BZX
New Agios Clinical Data from Ongoing Phase 1 Trial of AG-221 Continue to Show Complete and Durable Remissions in Patients with Difficult to Treat Hematologic Malignancies 7:31 a.m. June 14, 2014 - BusinessWire - BZX
Agios Pharmaceuticals Announces that Celgene Exercised its Option to License AG-221 Under Global Strategic Collaboration 8:03 a.m. June 13, 2014 - BusinessWire - BZX
Agios Pharmaceuticals Initiates Multiple Ascending Dose Trial in Healthy Volunteers of AG-348 for the Potential Treatment of PK Deficiency, a Rare, Hemolytic Anemia 8:02 a.m. June 9, 2014 - BusinessWire - BZX
Strategic Acquisitions, Clinical Data Presentations, Research Grants, and Technical Updates - Analyst Notes on Acadia, Opko Health, Arrowhead Research, Agios Pharmaceuticals and Sangamo Biosciences 5:10 a.m. June 6, 2014 - PR Newswire - PRF
Flagship Ventures Commences Its Sixth VentureLabs™ Fellowship Program Focused On Entrepreneurial Innovation 9:00 a.m. June 5, 2014 - PR Newswire - PRF
Agios Pharmaceuticals to Present at the Goldman Sachs 35th Annual Global Healthcare Conference 9:03 a.m. June 4, 2014 - BusinessWire - BZX
Agios Pharmaceuticals to Present New Clinical Data from AG-221 Ongoing Phase 1 Study at the 19th Congress of the European Hematology Association 4:44 a.m. May 22, 2014 - BusinessWire - BZX
Business Highlights, Financial Results, and Leadership Appointments - Analyst Notes on PDL BioPharma, bluebird, Osiris, Agios and Ophthotech 7:00 a.m. May 19, 2014 - PR Newswire - PRF
Agios Pharmaceuticals Appoints Chris Bowden, M.D., as Chief Medical Officer 8:32 a.m. May 14, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

2026 Community Impact Week: Slam Dunk for Community Unity

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Pacira BioSciences Faces Shareholder Revolt in M&A Deal

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Duolingo Faces Lawsuit Over Alleged Investor Missteps

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

LEGO Mashes Star Wars and Marvel for Fans' Delight

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...